HRP20220479T1 - Spojevi - Google Patents
Spojevi Download PDFInfo
- Publication number
- HRP20220479T1 HRP20220479T1 HRP20220479TT HRP20220479T HRP20220479T1 HR P20220479 T1 HRP20220479 T1 HR P20220479T1 HR P20220479T T HRP20220479T T HR P20220479TT HR P20220479 T HRP20220479 T HR P20220479T HR P20220479 T1 HRP20220479 T1 HR P20220479T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- group
- alkyl
- hydrogen
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 206010011891 Deafness neurosensory Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 108700003601 dimethylglycine Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 1
- 229960001153 serine Drugs 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0217—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (9)
1. Spoj formule II:
[image]
gdje:
n je 1, 2, 3, 4, 5, 6, 7, 8 ili 9;
m je 0, 1, 2, 3 ili 4;
R1 je odabran iz skupine koju čine: C1-C12 alkil, C1-C12 supstituirani alkil, C1-C12 alkenil, C1-C12 supstituirani alkenil, C1-C12 alkinil i C1-C12 supstituirani alkinil;
R2 je odabran iz skupine koju čine: vodik,
[image]
PO(OY)2,
[image]
PO(OH)2, -C(=O)-Y i -CO-U;
Y je -Z-(CH2)q-W-Rb, ili -C(=O)-Y alternativno obrazuje amidnu vezu preko atoma azota na Y, u kom slučaju je Y odabran iz skupine koja se sastoji od: glicina, sarkozina, N,N-dimetil glicina, alanina, valina, leucina, izoleucina, lizina, ornitina, arginina, serina i treonina;
q je 0-4;
Z i W su neovisno odabrani iz skupine sastavljene od: CH2, O, S, NRc i Rb, pri čemu su Z i W po izboru zajedno uzeti, da bi oblikovali C3-C8 heterocikloalkilni ili C4-C10 heteroarilni ili biciklički sustav prstenova u kojem je jedan od prstenova C4-C10 heteroaril;
Rc je odabran iz skupine koju čine: vodik, C1-C4 alkil i C3-C6 cikloalkil;
Rb je odabran iz skupine koju čine: vodik, C1-C12 alkil, C1-C12 supstituirani alkil, C3-C8 cikloalkil, C3-C8 supstituirani cikloalkil, C3-C8 heterocikloalkil i C3-C8 supstituirani heterocikloalkil;
U je odabran iz skupine koju čine: piridin, 1,4-dihidropiridin, N-alkil-1,4-dihidropiridin i C-imidazol, ili je U odabran od arila, heteroarila ili heterocikloalkila;
R3 i R4 su zajedno vezani tako da oblikuju spirociklički sustav prstenova;
svaki R6 je neovisno odabran iz skupine sastavljene od: vodika, deuterijuma, CH3, F, 19F i 18F;
a pri čemu svaki heterociklički i heteroarilni prsten sadrži do četiri heteroatoma odabrana iz skupine sastavljene od: O, N i S;
pod uvjetom da kada su i Z i W heteroatomi, vrijednost q ne može biti 1;
ili njegov tautomer i/ili farmaceutski prihvatljiva sol.
2. Spoj sukladno patentnom zahtjevu 1, gdje je m 0, R1 je C1-C12 alkil i R3 i R4 zajedno oblikuju spirociklički sustav prstenova.
3. Spoj sukladno patentnom zahtjevu 1, gdje je m 1 ili 2, R1 je C1-C12 alkil, R3 i R4 zajedno oblikuju spirociklički sustav prstenova, a R6 je odabran iz skupine sastavljene od: vodika, deuterija, F, 19F i 18F.
4. Spoj odabran od slijedećih struktura:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
ili njegov tautomer i/ili farmaceutski prihvatljiva sol.
5. Pripavak koji sadrži najmanje jedan spoj od navedenih u bilo kojem od patentnih zahtjeva 1-4, ili njihove tautomere, stereoizomere, soli, solvate ili hidrate.
6. Farmaceutski pripravak koja sadrži najmanje jedan spoj od navedenih sukladna bilo kojem od patentnih zahtjeva 1-4, ili njihove tautomere, stereoizomere, soli, solvate ili hidrate, i farmaceutski prihvatljiv nosač ili ekscipijens.
7. Farmaceutski pripravak sukladno patentnom zahtjevu 6, koji nadalje sadrži N-heksanoički-L-tirozin-L-izoleucin-(6)-aminoheksanoički amid.
8. Spoj sukladno bilo kojem od patentnih zahtjeva 1-4, ili farmaceutski pripravak sukladno patentnom zahtjevu 6 ili 7, za uporebu u postupku liječenja neurodegenerativne bolesti.
9. Spoj sukladno bilo kojem od patentnih zahtjeva 1-4, ili farmaceutski pripravak sukladno patentnom zahtjevu 6 ili 7, za uporabu sukladno patentnom zahtjevu 8, pri čemu je neurodegenerativna bolest odabrana iz skupine koju čine: Alzheimerova bolest, Parkinsonova bolest, amiotrofična lateralna skleroza, druge demencije i neurodegenerativne bolesti, povreda leđne moždine, traumatska povreda mozga, senzorneuralni gubitak sluha i vida, a poželjno je Alzheimerova bolest ili Parkinsonova bolest.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662344305P | 2016-06-01 | 2016-06-01 | |
PCT/US2017/035547 WO2017210489A1 (en) | 2016-06-01 | 2017-06-01 | Compounds |
EP17807519.8A EP3464336B1 (en) | 2016-06-01 | 2017-06-01 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220479T1 true HRP20220479T1 (hr) | 2022-05-27 |
Family
ID=60478958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220479TT HRP20220479T1 (hr) | 2016-06-01 | 2017-06-01 | Spojevi |
Country Status (14)
Country | Link |
---|---|
US (2) | US11021514B2 (hr) |
EP (2) | EP3464336B1 (hr) |
JP (3) | JP2019525947A (hr) |
CN (3) | CN116655730A (hr) |
AU (3) | AU2017273857B2 (hr) |
CA (1) | CA3026074A1 (hr) |
DK (1) | DK3464336T3 (hr) |
ES (1) | ES2912035T3 (hr) |
HR (1) | HRP20220479T1 (hr) |
LT (1) | LT3464336T (hr) |
PL (1) | PL3464336T3 (hr) |
RS (1) | RS63143B1 (hr) |
SI (1) | SI3464336T1 (hr) |
WO (1) | WO2017210489A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
CA3223668A1 (en) * | 2021-07-23 | 2023-01-26 | Athira Pharma, Inc. | Methods of treating parkinson's disease and/or lewy body disease or disorder(s) |
TW202406554A (zh) | 2022-05-04 | 2024-02-16 | 美商雅斯娜製藥公司 | 治療神經發炎性病況之方法 |
WO2023215376A1 (en) | 2022-05-04 | 2023-11-09 | Athira Pharma, Inc. | Methods of treating neuropathies |
WO2023215378A1 (en) | 2022-05-04 | 2023-11-09 | Athira Pharma, Inc. | Methods of treating fibrosis |
CN114907288B (zh) * | 2022-05-13 | 2023-12-08 | 中国医学科学院医药生物技术研究所 | 硝基苯类化合物在制备铜绿假单胞菌群体感应抑制剂中的应用 |
Family Cites Families (238)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4639456A (en) | 1980-06-10 | 1987-01-27 | Omnichem S.A. | Vinblastin-23-oyl amino acid derivatives |
GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
DE3320175A1 (de) | 1983-06-03 | 1984-12-06 | Boehringer Mannheim Gmbh, 6800 Mannheim | Aminosaeure- bzw. peptidderivate, verfahren zu deren herstellung und verwendung als arzneimittel |
US4477440A (en) | 1983-09-14 | 1984-10-16 | Merck & Co., Inc. | Renin inhibitors containing an n-terminal disulfide cycle |
EP0163237A3 (en) | 1984-05-29 | 1988-04-27 | Merck & Co. Inc. | Di- and tri-peptidal renin inhibitors |
JPS63503380A (ja) | 1986-01-16 | 1988-12-08 | アボット・ラボラトリーズ | ペプチド類似体 |
US5378691A (en) | 1988-04-14 | 1995-01-03 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Amino acid derivatives |
AU4035189A (en) | 1988-08-19 | 1990-03-23 | Upjohn Company, The | Renin inhibitory peptides containing suleptanic acid or derivatives thereof |
US5180816A (en) | 1988-08-24 | 1993-01-19 | Centocor | One vial method for labeling protein/linker conjugates with technetium-99M |
EP0444156A4 (en) | 1988-11-21 | 1992-12-09 | Abbott Laboratories | Method for treating vascular diseases |
DE3912829A1 (de) | 1989-04-19 | 1990-10-25 | Bayer Ag | Verwendung von renininhibitorischen peptiden als mittel gegen retroviren |
DE4004820A1 (de) | 1989-08-05 | 1991-04-25 | Bayer Ag | Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
DE3915361A1 (de) | 1989-05-11 | 1990-11-15 | Merck Patent Gmbh | Cyclopeptide |
US5240913A (en) | 1989-08-18 | 1993-08-31 | Biogen, Inc. | Inhibitors of thrombin |
CA2035917C (en) | 1990-02-13 | 2001-10-02 | John L. Krstenansky | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
US5284828A (en) | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
AU648140B2 (en) | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
US5190924A (en) | 1991-02-13 | 1993-03-02 | Boc Health Care, Inc. | Peptide amides and amide dimers useful as muscle relaxants |
US5382569A (en) | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
EP0584290B1 (en) | 1991-05-16 | 2000-08-30 | Warner-Lambert Company | Endothelin antagonists |
US5190922A (en) | 1991-06-04 | 1993-03-02 | Abbott Laboratories | Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands |
CA2071674C (en) | 1991-06-21 | 2003-08-19 | Kevin T. Chapman | Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme |
DE4122885A1 (de) | 1991-07-11 | 1993-01-21 | Hoechst Ag | Verfahren zur diastereoselektiven reduktiven pinakol-kupplung von homochiralen (alpha)-aminoaldehyden |
EP0533226A3 (en) | 1991-08-16 | 1993-08-18 | Merck & Co. Inc. | Novel chromophore containing compounds |
US6348570B1 (en) | 1991-08-16 | 2002-02-19 | Merck & Co., Inc. | Chromophore containing compounds and their use in determining interleukin-1β convertase activity |
US5223535A (en) | 1991-10-29 | 1993-06-29 | G. D. Searle & Co. | Propargyl glycine amino propargyl diol compounds for treatment of hypertension |
US5227401A (en) | 1991-10-29 | 1993-07-13 | G. D. Searle & Co. | Ethynyl alanine amino diol compounds for treatment of hypertension |
JPH05117169A (ja) | 1991-10-29 | 1993-05-14 | Mitsubishi Kasei Corp | クロロメチルケトンの製法 |
WO1993012076A1 (en) | 1991-12-13 | 1993-06-24 | Corvas International Inc. | Reagents for automated synthesis of peptide analogs |
EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
JPH05178890A (ja) | 1991-12-26 | 1993-07-20 | Banyu Pharmaceut Co Ltd | エンドセリン拮抗性化合物 |
AU3479593A (en) | 1992-01-31 | 1993-09-01 | Merck & Co., Inc. | Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme |
EP0627926B1 (en) | 1992-02-21 | 1998-08-05 | Merck & Co., Inc. (a New Jersey corp.) | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME |
US5430062A (en) | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
WO1993023357A1 (en) | 1992-05-21 | 1993-11-25 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
EP0647239A4 (en) | 1992-06-24 | 1997-07-02 | Univ Washington | ANGIOTENSIN IV PEPTIDES, AND RECEPTOR. |
AU679945B2 (en) | 1992-09-24 | 1997-07-17 | Chiron Corporation | Synthesis of N-substituted oligomers |
EP0600832A1 (de) | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Diaminobenzoe- und Diaminophthalsäurederivate und ihre Verfahren als Proteinkinase-Inhibitoren |
IL107719A0 (en) | 1992-12-21 | 1994-02-27 | Du Pont | Imidazolones their manufacture and their use as herbicides |
JPH06192199A (ja) | 1992-12-25 | 1994-07-12 | Mitsubishi Kasei Corp | ケトン誘導体 |
WO1994022906A1 (en) | 1993-03-26 | 1994-10-13 | Warner-Lambert Company | Inhibitors of endothelin converting enzyme |
DE4311021A1 (de) | 1993-03-31 | 1994-10-27 | Diagnostikforschung Inst | Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel |
WO1994028012A1 (en) | 1993-05-28 | 1994-12-08 | Warner-Lambert Company | Hydroxamate inhibitors of endothelin converting enzyme |
US5854388A (en) | 1993-06-24 | 1998-12-29 | Washington State University Research Foundation | Angiotensin IV peptides and receptor |
DE4321306A1 (de) | 1993-06-26 | 1995-01-05 | Sanol Arznei Schwarz Gmbh | Disulfide |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
DE4345062A1 (de) | 1993-12-31 | 1995-07-13 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von Viruserkrankungen |
US5686419A (en) | 1994-01-21 | 1997-11-11 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
US20010046668A1 (en) | 1994-10-21 | 2001-11-29 | G.D. Searle & Co. | Fluorescence polarization method for determining protease activity |
US5840698A (en) | 1994-10-27 | 1998-11-24 | Affymax Technologies N.V. | Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use |
US5831004A (en) | 1994-10-27 | 1998-11-03 | Affymax Technologies N.V. | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use |
EP0793673A1 (en) | 1994-11-24 | 1997-09-10 | Takeda Chemical Industries, Ltd. | Alpha-ketoamide derivatives as cathepsin l inhibitor |
EP0731107A1 (en) | 1995-02-13 | 1996-09-11 | Takeda Chemical Industries, Ltd. | Production of aldehyde derivatives |
JPH08262673A (ja) | 1995-03-22 | 1996-10-11 | Fuji Photo Film Co Ltd | 銀塩拡散転写法による画像形成方法 |
EP0822983A4 (en) | 1995-04-21 | 2004-12-15 | Merck & Co Inc | apopain |
US5798442A (en) | 1995-04-21 | 1998-08-25 | Merck Frosst Canada, Inc. | Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases |
AU6317996A (en) | 1995-07-07 | 1997-02-10 | Sagami Chemical Research Center | Peptide derivatives and angiotensin iv receptor agonist |
GB9517060D0 (en) | 1995-08-17 | 1995-10-25 | Ciba Geigy Ag | Acylated oligopeptide derivatives |
US5763576A (en) | 1995-10-06 | 1998-06-09 | Georgia Tech Research Corp. | Tetrapeptide α-ketoamides |
US5817757A (en) | 1995-10-30 | 1998-10-06 | Merck & Co., Inc. | Inhibitors of peptide binding to MHO class II proteins |
AU7525796A (en) | 1995-10-30 | 1997-05-22 | Merck & Co., Inc. | Novel inhibitors of peptide binding to mhc class ii proteins |
US6121489A (en) | 1996-03-05 | 2000-09-19 | Trega Biosciences, Inc. | Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein |
JP2000510453A (ja) | 1996-04-19 | 2000-08-15 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン遊離特性を有する化合物 |
SE9603461D0 (sv) | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
SE9603468D0 (sv) | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
SI9600371B (sl) | 1996-12-18 | 2005-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Etilidenski derivati tricikličnih karbapenemov |
DE69728164D1 (de) | 1996-12-27 | 2004-04-22 | Boehringer Ingelheim Ca Ltd | Peptidomimetische inhibitoren von der protease des menschlichen cytomegalovirus |
GB2324529A (en) | 1997-02-21 | 1998-10-28 | Merck & Co Inc | A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases |
BR9813554A (pt) | 1997-12-12 | 2001-07-24 | Fuji Yakuhin Kogyo Kk | Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase |
CA2225325A1 (en) | 1997-12-19 | 1999-06-19 | The University Of British Columbia | Hemiasterlin analogs |
US6468977B1 (en) | 1998-03-02 | 2002-10-22 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
US6022696A (en) | 1998-04-02 | 2000-02-08 | Washington State University Research Foundation | Methods of identifying agonists or antagonists of angiotensin IV |
GB9809664D0 (en) | 1998-05-06 | 1998-07-01 | Hoffmann La Roche | a-Ketoamide derivatives |
DE69941708D1 (de) | 1998-07-20 | 2010-01-07 | Ipsen Pharma | Pacap-peptidanaloga |
US6242563B1 (en) | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
JP2000250182A (ja) | 1999-03-04 | 2000-09-14 | Fuji Photo Film Co Ltd | カラー拡散転写写真画像形成方法 |
EP1059302A1 (en) | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
US20060233748A1 (en) | 2002-09-13 | 2006-10-19 | Ahmed Merzouk | Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease |
US20070160574A1 (en) | 2000-04-12 | 2007-07-12 | Ahmed Merzouk | Design of CXC chemokine analogs for the treatment of human diseases |
US20070116669A1 (en) | 2002-09-13 | 2007-05-24 | Chemokine Therapeutics Corporation | Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases |
AU4876701A (en) | 2000-04-14 | 2001-10-30 | Nippon Shinyaku Co. Ltd. | Peptide derivatives and medicinal compositions |
JP2002145898A (ja) | 2000-11-09 | 2002-05-22 | Ajinomoto Co Inc | 新規グリチルレチン酸誘導体及び甘味剤 |
FR2816509B1 (fr) | 2000-11-15 | 2004-02-06 | Sod Conseils Rech Applic | Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene |
JP2003040784A (ja) | 2001-01-31 | 2003-02-13 | Japan Science & Technology Corp | 血糖降下剤 |
EP1351992B1 (en) | 2001-01-16 | 2011-03-02 | Ramot at Tel Aviv University Ltd. | Hybrid peptides for treatment of bacteremia and septicemia |
CA2447023A1 (en) | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
TW200301079A (en) | 2001-12-21 | 2003-07-01 | Syngenta Participations Ag | Avermectin B1 derivatives having an aminosulfonyloxy substituent in the 4"-position |
CN1293042C (zh) | 2002-02-07 | 2007-01-03 | 远藤仁 | 芳香族氨基酸衍生物及其药物组合物 |
US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
US7056947B2 (en) | 2002-07-05 | 2006-06-06 | Georgia Tech Research Corp. | Aza-peptide epoxides |
US8013014B2 (en) | 2002-07-05 | 2011-09-06 | Georgia Tech Research Corporation | Aza-peptide epoxides |
WO2004005324A2 (en) | 2002-07-09 | 2004-01-15 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
WO2004018644A2 (en) | 2002-08-26 | 2004-03-04 | Wisconsin Alumni Research Foundation | HETEROGENEOUS FOLDAMERS CONTAINING α, β, AND/OR Ϝ-AMINO ACIDS |
WO2004078778A2 (en) * | 2003-03-03 | 2004-09-16 | Dyax Corp. | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF |
DE10320453A1 (de) | 2003-05-08 | 2004-11-25 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Bioisostere von Actinonin |
RS53476B (en) * | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
CA2534355A1 (en) | 2003-08-07 | 2005-02-17 | Enkam Pharmaceuticals A/S | Compounds comprising lpa |
US7118747B2 (en) | 2003-09-30 | 2006-10-10 | Pacific Northwest Biotechnology Inc. | AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents |
SE0302853D0 (sv) | 2003-10-29 | 2003-10-29 | Astrazeneca Ab | Chemical compounds |
CA2557631A1 (en) | 2004-02-18 | 2005-09-01 | Georgia Tech Research Corporation | Propenoyl hydrazides |
JP4502115B2 (ja) | 2004-04-23 | 2010-07-14 | 信越化学工業株式会社 | 含窒素有機化合物、化学増幅型レジスト材料及びパターン形成方法 |
JP5053836B2 (ja) | 2004-04-30 | 2012-10-24 | テラプトシス エス アー | カスパーゼ−2阻害剤およびそれらの生物学的適用 |
WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
US20060063803A1 (en) | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
US7521427B2 (en) | 2004-11-09 | 2009-04-21 | Georgia Tech Research Corporation | Peptidyl allyl sulfones |
WO2006061714A2 (en) | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
DE102005044319A1 (de) | 2005-09-16 | 2007-03-22 | Curacyte Chemistry Gmbh | 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
GB0522061D0 (en) | 2005-10-28 | 2005-12-07 | Glaxo Group Ltd | Chemical process |
US7705009B2 (en) | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
WO2007070372A2 (en) | 2005-12-09 | 2007-06-21 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
JP5079265B2 (ja) | 2006-06-13 | 2012-11-21 | ポリプラスチックス株式会社 | 安定化ポリアセタール樹脂の製造方法 |
EA019757B1 (ru) | 2006-06-15 | 2014-06-30 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая композиция с синергетическим противосудорожным эффектом |
CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
EP1873527A1 (en) | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
EP2046350A4 (en) | 2006-06-22 | 2011-09-14 | Biosurface Eng Tech Inc | COMPOSITIONS AND METHOD FOR THE RELEASE OF A BMP-2 AMPLIFIER / COACTIVATOR FOR REINFORCED OSTEOGENESIS |
US7910555B2 (en) | 2006-07-07 | 2011-03-22 | Washington State University Research Foundation | C-Met receptor regulation by angiotensin IV (AT4 ) receptor ligands |
US8236761B2 (en) | 2006-07-07 | 2012-08-07 | Washington State University Research Foundation | C-Met receptor regulation by angiotensin IV (AT4) receptor ligands |
US9066901B2 (en) | 2006-07-07 | 2015-06-30 | Washington State University | C-Met receptor regulation by angiotensin IV (AT4) receptor ligands |
EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
ATE458749T1 (de) | 2006-12-15 | 2010-03-15 | Giuseppe Campiani | Neuartige mit taxan verwandte peptide und deren verwendung |
EP1977765A1 (en) | 2007-04-03 | 2008-10-08 | Diatos | Peptide prodrugs |
BRPI0813647A2 (pt) | 2007-06-25 | 2014-12-23 | Neurogen Corp | Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados |
BRPI0814403A2 (pt) | 2007-07-02 | 2015-01-27 | Hoffmann La Roche | Devirados de imidazol como antagonistas de receptor ccr2 |
JP2010540584A (ja) | 2007-10-01 | 2010-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | Ccr受容体アンタゴニストとしてのn−複素環ビアリールカルボキサミド類 |
US8114640B2 (en) | 2007-10-30 | 2012-02-14 | The Regents Of The University Of Michigan | Macrocyclization of compounds from solid support using thioesterases |
EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
BRPI0907754A2 (pt) | 2008-02-08 | 2015-07-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos terapêuticos |
US9096649B2 (en) | 2008-02-08 | 2015-08-04 | Northern Antibiotics Ltd. | Polymyxin derivatives and uses thereof |
EP2285216A4 (en) | 2008-02-21 | 2012-09-19 | Sequoia Pharmaceuticals Inc | HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR |
CA2713716A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
CA2718959A1 (en) | 2008-03-21 | 2009-09-24 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
US8367680B2 (en) | 2008-03-28 | 2013-02-05 | Wisconsin Alumni Research Foundation | Antibacterial small molecules and methods for their synthesis |
WO2010014179A1 (en) | 2008-07-31 | 2010-02-04 | Duke University | Photolabile caged transition metal complexes and methods of using the same |
JP2012500284A (ja) | 2008-08-19 | 2012-01-05 | フェリング ベスローテン フェンノートシャップ | ペプチド性pth受容体アゴニスト |
US8772229B2 (en) | 2008-10-03 | 2014-07-08 | The Johns Hopkins University | Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase as potential therapeutic agents for obesity and diabetes |
WO2010042212A2 (en) | 2008-10-10 | 2010-04-15 | Dara Biosciences, Inc. | Methods for treating or preventing pain using spicamycin derivatives |
CA2747195A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
US8697632B2 (en) | 2008-12-19 | 2014-04-15 | Indiana University Research And Technology Corporation | Amide based insulin prodrugs |
US8835602B2 (en) | 2009-03-06 | 2014-09-16 | Indian Institute Of Science | Templates for nucleation and propagation of peptide secondary structure |
WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
CA2999345A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
WO2010151644A2 (en) | 2009-06-26 | 2010-12-29 | Brandeis University | Antineoplastic hydrogels, and enzyme-instructed preparations thereof |
SG177709A1 (en) | 2009-07-21 | 2012-02-28 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
RU2636738C2 (ru) | 2009-09-25 | 2017-11-28 | Шайр Орфан Терапис ГмбХ | Новые агонисты npr-b |
US8551938B2 (en) | 2009-09-25 | 2013-10-08 | Alcon Research, Ltd. | NPR-B agonists |
WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
EP3219713A1 (en) | 2010-01-15 | 2017-09-20 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
GB201013513D0 (en) | 2010-08-11 | 2010-09-22 | Novacta Biosystems Ltd | Formulations |
US9102712B2 (en) | 2010-08-27 | 2015-08-11 | New York University | Dendrimeric peptides, pharmaceutical compositions and methods of using the same |
EP2428503B1 (de) | 2010-09-10 | 2014-12-10 | Justus-Liebig-Universität Gießen | Synthese von tripodalen Catecholderivaten mit einem flexiblen Grundgerüst zur Funktionalisierung von Oberflächen |
BR112013022946A2 (pt) | 2011-03-09 | 2017-07-18 | Signature Therapeutics Inc | pró-fármacos de agentes ativos com ligantes heterocíclocos |
US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
EP2709650B1 (en) * | 2011-04-02 | 2017-02-08 | Washington State University | Hepatocyte growth factor mimics as therapeutic agents |
CN102838523A (zh) | 2011-06-23 | 2012-12-26 | 南开大学 | 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途 |
GB201110938D0 (en) | 2011-06-27 | 2011-08-10 | Iti Scotland Ltd | Compounds |
EP2751128B1 (en) | 2011-08-30 | 2021-03-03 | United Kingdom Research and Innovation | Cell-penetrating peptides having a central hydrophobic domain |
EP4074694A1 (en) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
EP2814807A4 (en) | 2012-02-16 | 2015-10-07 | Rqx Pharmaceuticals Inc | LINEAR PEPTIDANTIBIOTICS |
EP2820150A1 (en) | 2012-03-01 | 2015-01-07 | Novo Nordisk A/S | N-terminally modified oligopeptides and uses thereof |
US20140094413A1 (en) * | 2012-04-02 | 2014-04-03 | Washington State University | Hepatocyte growth factor (hgf) mimics as therapeutic agents |
JP2015515478A (ja) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物及びそれらの併用療法 |
JO3109B1 (ar) | 2012-05-10 | 2017-09-20 | Ferring Bv | منبهات لمستقبلات v1a |
JP2015516436A (ja) | 2012-05-11 | 2015-06-11 | アッヴィ・インコーポレイテッド | Nampt阻害薬 |
JP2015520752A (ja) | 2012-05-11 | 2015-07-23 | アッヴィ・インコーポレイテッド | Nampt阻害薬としてのピリダジンおよびピリジン誘導体 |
WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
WO2014052766A1 (en) | 2012-09-27 | 2014-04-03 | Washington State University | Hepatocyte growth factor mimics as therapeutic agents |
DE112013005259T5 (de) | 2012-11-01 | 2015-09-24 | Evonik Degussa Gmbh | Verfahren zur enzymatischen Bildung von Amidbindungen |
WO2014074789A1 (en) | 2012-11-08 | 2014-05-15 | Brandeis University | Hydrogelators comprising d-amino acids |
UA111925C2 (uk) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
EP2746262A1 (en) | 2012-12-19 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds for combating phytopathogenic fungi |
EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
US10570151B2 (en) | 2013-03-15 | 2020-02-25 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
CN105431447A (zh) | 2013-03-15 | 2016-03-23 | 阿达拉塔合伙有限公司 | Pcsk9的小分子调节剂和其使用方法 |
JP2016526023A (ja) | 2013-05-08 | 2016-09-01 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Stat6阻害剤 |
RU2732440C2 (ru) | 2013-06-24 | 2020-09-16 | Кэнбас Ко., Лтд. | Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями |
RU2016107436A (ru) | 2013-08-14 | 2017-09-19 | АрКьюЭкс ФАРМАСЬЮТИКЛС, ИНК. | Линейные пептидные антибиотики |
US10123960B2 (en) | 2013-11-15 | 2018-11-13 | Pcr Technology Holdings, Lc | Methods for treating of skin conditions with retinoid double conjugate compounds |
CA2934144A1 (en) | 2013-12-20 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Fused imidazolyl derivatives, their preparation and use as medicaments |
JP6295702B2 (ja) | 2014-02-14 | 2018-03-20 | 東洋インキScホールディングス株式会社 | 反応性単量体、およびそれを用いた重合性組成物 |
EP2910236B1 (de) | 2014-02-24 | 2020-02-12 | Ivoclar Vivadent AG | Dentalmaterialien auf der Basis von geruchsarmen Thiolen |
EP3137597A1 (en) | 2014-04-30 | 2017-03-08 | University Of Oslo | Systems and methods for stem cell differentiation |
KR20170001962A (ko) | 2014-05-15 | 2017-01-06 | 제이 파마 가부시끼가이샤 | 항 악성 종양제 조성물 |
US9475854B2 (en) * | 2014-05-23 | 2016-10-25 | Washington State University | Lead compound for otoprotection: targeting HGF signaling with dihexa |
JP6158754B2 (ja) | 2014-06-04 | 2017-07-05 | 信越化学工業株式会社 | レジスト下層膜形成用組成物、及びパターン形成方法 |
US20170121646A1 (en) | 2014-07-03 | 2017-05-04 | Novozymes A/S | Improved Stabilization of Non-Protease Enzyme |
TWI515225B (zh) | 2014-07-10 | 2016-01-01 | 國立交通大學 | 胜肽分子材料 |
EP2975046A1 (en) | 2014-07-16 | 2016-01-20 | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth | Novel compounds |
SG11201701169XA (en) | 2014-08-15 | 2017-03-30 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrrolopyrimidine compounds used as tlr7 agonist |
EP3197912B1 (en) | 2014-09-24 | 2023-01-04 | Indiana University Research & Technology Corporation | Lipidated amide-based insulin prodrugs |
US9388214B2 (en) | 2014-11-05 | 2016-07-12 | Ferring B.V. | V1A receptor agonists |
DK3234093T3 (da) | 2014-12-19 | 2020-08-17 | Novozymes As | Proteasevarianter og polynukleotider, som koder for dem |
WO2016123576A1 (en) | 2015-01-30 | 2016-08-04 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
US9969719B2 (en) | 2015-03-11 | 2018-05-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug |
JP6873043B2 (ja) | 2015-03-23 | 2021-05-19 | ポリフォー・アクチェンゲゼルシャフトPolyphor Ag | ベータ−ヘアピンペプチド模倣体 |
CN104788537B (zh) | 2015-03-31 | 2018-03-13 | 中国科学院长春应用化学研究所 | 一种四肽化合物及其制备方法和应用 |
HUE061954T2 (hu) | 2015-05-01 | 2023-09-28 | Ironwood Pharmaceuticals Inc | Vastagbél tisztítására és gyomor-bélrendszeri rendellenességek kezelésére szolgáló készítmények |
WO2016182898A1 (en) | 2015-05-08 | 2016-11-17 | Xenoport, Inc. | Methods of use for monomethyl fumarate and prodrugs thereof |
CN114874288A (zh) | 2015-07-09 | 2022-08-09 | 米梅奥亨制药公司 | β-转角环状模拟肽盐的溶液相合成和结晶 |
US20170022149A1 (en) | 2015-07-25 | 2017-01-26 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
MX2018007451A (es) | 2015-12-18 | 2018-11-09 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas con lisina c-terminal. |
US10646463B2 (en) | 2016-01-11 | 2020-05-12 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
ES2906780T3 (es) | 2016-01-28 | 2022-04-20 | Novozymes As | Método de limpieza de un instrumento médico o dental |
US20190055283A1 (en) | 2016-02-29 | 2019-02-21 | Ohio State Innovation Foundation | Aza-peptide aldehydes and ketones |
WO2017151886A1 (en) | 2016-03-02 | 2017-09-08 | Stealth Biotherapeutics Corp | Methods and compositions for the treatment and prevention of pulmonary arterial hypertension |
US20190083574A1 (en) | 2016-03-29 | 2019-03-21 | Ohio State Innovation Foundation | Thermogenic compositions and methods |
US11634404B2 (en) | 2016-04-14 | 2023-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective D3 dopamine receptor agonists and methods of their use |
EP4000690A1 (en) | 2016-05-19 | 2022-05-25 | Stealth BioTherapeutics Inc. | Compositions and methods for the prevention and treatment of mitochondrial myopathies |
WO2017210188A1 (en) | 2016-05-31 | 2017-12-07 | Novozymes A/S | Stabilized liquid peroxide compositions |
AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
WO2017217855A1 (en) | 2016-06-17 | 2017-12-21 | Erasmus University Medical Center Rotterdam | Geminoid lipopeptide compounds and their uses |
US10398760B2 (en) | 2016-06-30 | 2019-09-03 | Gabriel Rusanescu | Method of treating pain using agents that promote neuronal differentiation |
KR102200264B1 (ko) | 2016-07-12 | 2021-01-11 | 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 | Ppar 작용제인 피롤리딘 유도체 |
WO2018014862A1 (zh) | 2016-07-22 | 2018-01-25 | 南京明德新药研发股份有限公司 | S1p1激动剂及其应用 |
WO2018035615A1 (en) | 2016-08-26 | 2018-03-01 | Thrasos Therapeutics Inc. | Compositions and methods for the treatment of inflammatory bowel diseases |
US9611297B1 (en) | 2016-08-26 | 2017-04-04 | Thrasos Therapeutics Inc. | Compositions and methods for the treatment of cast nephropathy and related conditions |
WO2018035617A1 (en) | 2016-08-26 | 2018-03-01 | Thrasos Therapeutics Inc. | Antibiotic carrier conjugates for the treatment of kidney infections |
PE20190979A1 (es) | 2016-09-15 | 2019-07-09 | Boehringer Ingelheim Int | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 |
CN110023474A (zh) | 2016-09-29 | 2019-07-16 | 诺维信公司 | 酶用于洗涤的用途、洗涤方法和器皿洗涤组合物 |
EP3342779A1 (en) | 2016-12-27 | 2018-07-04 | Zedira GmbH | Inhibitors of transglutaminases |
EP3345917B1 (en) | 2017-01-05 | 2021-11-17 | Bacoba AG | Antiprotozoal compounds |
CA3049889A1 (en) | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
EP3585800A4 (en) | 2017-02-22 | 2021-06-02 | The Universite de Montreal | NEW HISTOCOMPATIBILITY MINOR ANTIGENS AND THEIR USES |
SG11201908856PA (en) | 2017-03-24 | 2019-10-30 | Agency Science Tech & Res | Stapled peptides |
US10738082B2 (en) | 2017-04-07 | 2020-08-11 | University Of South Florida | One-bead-two-compound macrocyclic library and methods of preparation and use |
US20180340008A1 (en) | 2017-05-24 | 2018-11-29 | Bioxiness Pharmaceuticals, Inc. | Antibiotic oligopeptide mimetics |
CN108117582A (zh) | 2017-12-30 | 2018-06-05 | 浙江大学 | 大环环氧酮肽类化合物及其制备方法和医药用途 |
-
2017
- 2017-06-01 AU AU2017273857A patent/AU2017273857B2/en active Active
- 2017-06-01 ES ES17807519T patent/ES2912035T3/es active Active
- 2017-06-01 CN CN202310097199.3A patent/CN116655730A/zh active Pending
- 2017-06-01 HR HRP20220479TT patent/HRP20220479T1/hr unknown
- 2017-06-01 JP JP2019515778A patent/JP2019525947A/ja active Pending
- 2017-06-01 WO PCT/US2017/035547 patent/WO2017210489A1/en unknown
- 2017-06-01 EP EP17807519.8A patent/EP3464336B1/en active Active
- 2017-06-01 CA CA3026074A patent/CA3026074A1/en active Pending
- 2017-06-01 CN CN202310310636.5A patent/CN116731101A/zh active Pending
- 2017-06-01 US US16/306,277 patent/US11021514B2/en active Active
- 2017-06-01 EP EP22161834.1A patent/EP4067368A1/en active Pending
- 2017-06-01 LT LTEPPCT/US2017/035547T patent/LT3464336T/lt unknown
- 2017-06-01 RS RS20220383A patent/RS63143B1/sr unknown
- 2017-06-01 PL PL17807519T patent/PL3464336T3/pl unknown
- 2017-06-01 DK DK17807519.8T patent/DK3464336T3/da active
- 2017-06-01 CN CN201780046512.3A patent/CN109563144B/zh active Active
- 2017-06-01 SI SI201731129T patent/SI3464336T1/sl unknown
-
2021
- 2021-04-12 US US17/228,481 patent/US20210340176A1/en active Pending
- 2021-11-09 AU AU2021266222A patent/AU2021266222B2/en active Active
- 2021-12-27 JP JP2021211913A patent/JP7203943B2/ja active Active
-
2022
- 2022-12-27 JP JP2022209881A patent/JP2023036883A/ja active Pending
-
2023
- 2023-12-22 AU AU2023285937A patent/AU2023285937A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021266222B2 (en) | 2023-10-05 |
DK3464336T3 (da) | 2022-05-09 |
US11021514B2 (en) | 2021-06-01 |
CA3026074A1 (en) | 2017-12-07 |
LT3464336T (lt) | 2022-05-10 |
AU2017273857A1 (en) | 2018-12-20 |
US20200010504A1 (en) | 2020-01-09 |
EP3464336A4 (en) | 2020-01-15 |
CN109563144B (zh) | 2023-03-28 |
EP3464336A1 (en) | 2019-04-10 |
AU2017273857B2 (en) | 2021-08-19 |
AU2023285937A1 (en) | 2024-01-25 |
US20210340176A1 (en) | 2021-11-04 |
CN116655730A (zh) | 2023-08-29 |
ES2912035T3 (es) | 2022-05-24 |
JP2022051738A (ja) | 2022-04-01 |
PL3464336T3 (pl) | 2022-05-16 |
EP3464336B1 (en) | 2022-03-16 |
EP4067368A1 (en) | 2022-10-05 |
SI3464336T1 (sl) | 2022-06-30 |
CN109563144A (zh) | 2019-04-02 |
WO2017210489A1 (en) | 2017-12-07 |
RS63143B1 (sr) | 2022-05-31 |
AU2021266222A1 (en) | 2021-12-02 |
JP2023036883A (ja) | 2023-03-14 |
JP2019525947A (ja) | 2019-09-12 |
JP7203943B2 (ja) | 2023-01-13 |
CN116731101A (zh) | 2023-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220479T1 (hr) | Spojevi | |
HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
NZ627036A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
HRP20180447T1 (hr) | Derivati kinazolina za liječenje virusnih infekcija i drugih bolesti | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
HRP20210775T1 (hr) | Predlijekovi fenolnih agonista trpv1 | |
PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
MY166866A (en) | Heterocyclic derivative and pharmaceutical drug | |
JP2016501223A5 (hr) | ||
MX2017015496A (es) | Fosforilacion selectiva sin disolvente. | |
MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
CY1118107T1 (el) | Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr | |
MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
MX2018009944A (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. | |
GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
ES2667477T3 (es) | Compuestos heterobiciclo-sustituidos-[1,2,4]triazolo[1,5-c]quinazolin-5-amina adecuados para el tratamiento o la prevención de trastornos del sistema nervioso central | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora |